First human trial launches for targeted radiation therapy against Hard-to-Treat neuroendocrine tumors
NCT ID NCT06148636
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new radioactive drug, [212Pb] VMT-α-NET, in 24 adults with advanced neuroendocrine tumors that have not responded to other treatments. The main goal is to find a safe dose for future studies, not to treat the disease. Participants receive up to two infusions of the drug along with amino acids to protect the kidneys.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[212Pb] VMT-α-NET (a radioactive drug)
What this could lead to
If successful, this could help determine a safe dose for future trials that might control tumor growth in patients with neuroendocrine tumors.
What could go wrong
This is an early, first-in-human safety study with only 24 participants. It is not designed to provide therapeutic benefit, and the drug may cause kidney damage or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Holden Comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa, 52242, United States